Asian markets traded lower on Friday, following overnight sell-off on Wall Street as trade war tensions between US and China escalated and fuelled risk-off mood. Japan's Nikkei share average led the losses in the region with a steel cut of over 5%.

Japan's Nikkei 225 plunged 5.46%, while the Topix tanked 5.05%.

The US stock market tumbled deeply into the red on Thursday as the White House clarified its plan for a massive 145% tariff on China, escalating a trade war.

Here's a table showing how US stocks performed on Thursday:

Source: Equitymaster

At present, the BSE Sensex is trading 1,110 points higher, and the NSE Nifty is trading 362 points higher.

Cipla, Tata Motors, and Hindalco are among the top gainers today.

TCS and Asian Paints, on the other hand, are among the top losers today.

The BSE Midcap index is trading 1.6% higher, and the BSE Smallcap index is trading 1.9% higher.

Sectoral indices are trading on a positive note today, with stocks in the metal sector, auto sector, and realty sector witnessing buying speer.

The rupee is trading at Rs 86.2 against the US dollar.
 

SJVN Releases Land Compensation

State-owned SJVN on Thursday said it has released land compensation of Rs 2.7 bn for the 3,097 MW Etalin Hydro Power Project in Dibang Valley, Arunachal Pradesh. The project aims to construct two dams - on Dri River and on the Talo (Tangon) River - along with an underground powerhouse complex, the power producer company said in a statement.

According to the statement, the project is scheduled for commissioning in December 2033.

In a significant step towards accelerating hydro-power development in Arunachal 2.7 bn as land compensation for the 3,097 MW Etalin Hydro Electric Project in Dibang Valley.

The land compensation amount was deposited in the joint account of DC & DLRSO, Dibang Valley on March 26, 2025, Raj Kumar Chaudhary, Chairman & Managing Director (Additional Charge) of SJVN, informed during the review meeting.
 

GAIL Commissions Dhamra Pipeline Project

Currently transports 12.26 MMSCMD of natural gas along the project route

GAIL (India) has completed the laying of over 97.6 % of the integrated Jagdishpur Haldia Bokaro - Dhamra Pipeline (JHBDPL), popularly known as Pradhan Mantri Urja Ganga, carrying Natural Gas to the Eastern and North-Eastern part of India. Of this, almost 96.6 % has been put under commercial operations.

The integrated JHBDPL including the Barauni Guwahati Pipeline has an authorized pipeline length of 3,306 km and passes through Uttar Pradesh, Bihar, Jharkhand, Odisha, West Bengal and Assam.

Presently, 3,227 km of pipeline section has been laid and 3,119 km of Pipeline Section including Phulpur Dobhi Bokaro Durgapur, Bokaro Angul Dhamra, Dobhi Barauni Guwahati Pipeline sections have already been put under commercial operation.

The pipeline is presently transporting 12.26 Million Standard Cubic meters per Day (MMSCMD) of Natural Gas.

With respect to the Durgapur Haldia Section (294 km), GAIL has already put 132 km of the Pipeline section up to Kolkata under commercial operation.

Further out of balance, 162 km of pipeline section to Haldia, and 103 km of pipeline laying have been completed. GAIL is also laying Dhamra Haldia Section having an authorized pipeline length of 240 km of which GAIL has already laid 198 km of pipeline.

Biocon Share Price is the Focus

Biocon share price will remain in focus on April 11 following the company's subsidiary receiving US Food and Drug Administration (USFDA) approval for a cancer drug.

Biocon Biologics, a subsidiary of Biocon, received USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use.

JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab).

JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis

- combating cancer by restricting blood supply to the tumor.

The approval of JOBEVNE expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb).

The company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY.

The company board at its meeting held on April 04 approved the issuance of commercial papers up to an amount not exceeding Rs 600 crore in one or more tranches on a private placement basis.

More By This Author: